179 search results for: Clinical Management
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.
The Multifactorial Burdens of Bullous Pemphigoid
Professor Dédée Murrell explains the challenges in managing patients with bullous pemphigoid at EADV 2025.
The Impacts of Delayed Diagnosis and Treatment in Bullous Pemphigoid
Professor Dédée Murrell highlights the importance of early diagnosis in bullous pemphigoid at EADV 2025
Assessing EoE: Using Endoscopic Features to Assess Disease Status
Expert gastroenterologist Dr. Ikuo Hirano highlights the endoscopic features in EoE and reviews the EREFS scoring system to assess disease activity.
Assessing EoE: Assessing Histologic Features in EoE
Expert gastroenterologist Dr. Ikuo Hirano reviews the histologic features of EoE and provides insights on their assessment.
Going Beyond the Scope in Eosinophilic Esophagitis
This infographic explores distensibility in EoE, including assessment with EndoFLIP.
Importance of Monitoring and Maintenance in EoE
Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.
World Anosmia Awareness Day
Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
FeNO as a Biomarker for Type 2 Asthma
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
IgE as a Biomarker for Type 2 Asthma
Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.
